The Rise of Psychedelic Retreats Signals a Booming — and Unregulated — Wellness Frontier

A renewed cultural fascination with the perceived therapeutic potential of psychedelic substances has sparked a wave of books, documentaries, and global conferences dedicated to their use. Now, that momentum has extended into a rapidly expanding industry: psychedelic retreats.

Across the world, hundreds of operators are offering multi-day immersive experiences where participants pay for guided, drug-assisted sessions that claim to foster psychological healing, emotional clarity, and personal transformation. While many of these retreats emphasize safety protocols and structured environments, researchers caution that they still carry a “potential for physical, psychological, and interpersonal harms,” according to a recent study published in JAMA Network Open.

Despite growing public interest, no psychedelic substances have yet received full federal approval in the United States. However, regulatory change may be on the horizon. In a significant policy shift, Donald Trump recently signed an executive order directing the Food and Drug Administration to accelerate the review of psychedelic compounds showing promise in treating conditions such as post-traumatic stress disorder. The order also calls for law enforcement agencies to ease restrictions on any psychedelic therapies that gain FDA approval.

So far, progress has been limited. The psychoactive drug MDMA — one of the most closely studied candidates — was rejected by regulators in 2024 due to unresolved concerns regarding both safety and clinical effectiveness.

Experts stress that psychedelics should not be approached casually. John Krystal, a psychiatrist at Yale School of Medicine, describes their use as “a serious medical procedure that carries risks that must be carefully managed.”

Industry advocates argue that today’s retreats are far more structured than their underground predecessors of past decades. Increased visibility has driven demand, enabling operators to invest in medical staff, coaching frameworks, and safety measures. Yet, despite this evolution, the sector remains largely unregulated — raising critical questions about consistency, accountability, and participant protection.

In the United States, the substances commonly used in these retreats — including psilocybin, ayahuasca, MDMA, and LSD — remain illegal under federal law. While some organizations claim protection under religious exemptions, only a limited number, such as the Native American Church, have formally secured such status. As a result, many retreats are hosted in countries like Peru and Brazil, where certain psychedelic practices have long-standing cultural and legal acceptance.

Even in these settings, there are no universal standards governing how participants are screened, prepared, or supported after their experiences. According to Joshua White, founder of the Fireside Project, the lack of oversight raises the risk of a “race to the bottom,” where diminished accountability could compromise participant safety.

Due diligence, therefore, becomes essential. Experts recommend that prospective attendees carefully evaluate retreat operators, including the qualifications of staff, emergency preparedness, proximity to medical facilities, and the level of psychological support provided before and after the experience. Researchers have noted wide variability across retreats, with some even offering multiple substances within a single program. While medical professionals are often present, their roles are not always clearly defined — and in some cases, they may participate in the psychedelic sessions themselves, potentially limiting their ability to respond in emergencies.

Screening processes present another area of concern. Although many retreats exclude individuals with serious mental health conditions such as schizophrenia, they typically rely on self-reported medical histories. This system introduces risk, as individuals seeking relief may withhold critical information to gain access. As experts warn, psychedelics can exacerbate certain psychiatric conditions, making thorough and reliable screening essential.

Medication management is equally complex. A significant number of retreats require participants to discontinue antidepressants prior to treatment, sometimes for extended “washout periods.” However, safely tapering off such medications can take weeks and should be conducted under medical supervision. Abrupt discontinuation increases the risk of relapse or worsening symptoms — a concern highlighted by Jeffrey Lieberman, who emphasizes the importance of close monitoring during this process.

While some of the rationale for discontinuing medications is grounded in scientific caution — particularly the risk of serotonin imbalance — critics suggest that retreat operators may also be motivated by a desire to enhance the intensity of the psychedelic experience itself.

As the psychedelic retreat industry continues to expand, it sits at the intersection of wellness culture, emerging science, and regulatory uncertainty. For participants, the promise of transformation remains compelling — but so too does the responsibility to navigate an evolving landscape where the safeguards are still catching up to the demand.